 |
3 Products |  |
155 Diseases | | 3 Products |
|
3 Trials |  |
277 News |  |
| 12» |
- | VPM1002 / SAKK, Serum Institute of India
Journal: Sex Differences in Vaccine-Induced Immunity and Protection Against Mycobacterium tuberculosis. (Pubmed Central) - Jun 26, 2025
In this study, we vaccinated male and female C57BL/6 mice with BCG and 2 recombinant derivatives, VPM1002 and BCG?BCG1419c, and assessed their protection against Mycobacterium tuberculosis (Mtb) HN878...Vaccination of males with BCG?BCG1419c, but not BCG, enhanced CD8 T-cell and B-cell recall responses in vaccine-draining lymph nodes, and reduced lung inflammation after Mtb challenge. These findings underscore the impact of sex differences on vaccine efficacy and suggest that future research should consider sex as a biological variable to optimize TB vaccination strategies.
- ||||||| VPM1002 / SAKK, Serum Institute of India
Trial completion: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (clinicaltrials.gov) - May 19, 2025
P2/3, N=2000, Completed, Sponsor: Serum Institute of India Pvt. Ltd.
These findings underscore the impact of sex differences on vaccine efficacy and suggest that future research should consider sex as a biological variable to optimize TB vaccination strategies. Active, not recruiting --> Completed
- ||||||| VPM1002 / SAKK, Serum Institute of India
Trial completion, Trial completion date, Trial primary completion date: Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (clinicaltrials.gov) - Feb 11, 2025
P3, N=6940, Completed, Sponsor: Serum Institute of India Pvt. Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Oct 2024 | Trial primary completion date: Dec 2025 --> Oct 2024
- | recombinant human erythropoietin / Max Planck Institute, Pfizer
Journal: Tolerability and first hints for potential efficacy of motor-cognitive training under inspiratory hypoxia in health and neuropsychiatric disorders: A translational viewpoint. (Pubmed Central) - Oct 15, 2024
Erythropoietin in serum increases under hypoxia and flow cytometry analysis of blood reveals several immune cell types to be mildly modulated by hypoxia. To obtain reliable information regarding the "add-on" value of inspiratory on top of functional hypoxia, induced by motor-cognitive training, a single-blind study-with versus without inspiratory hypoxia-is essential and outlined here.
- | recombinant human erythropoietin / Max Planck Institute, Pfizer
Preclinical, Journal: Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus. (Pubmed Central) - Oct 4, 2024
Metabolism and inhibitory potential of interneuron subgroups are compromised, leading to greater excitability of pyramidal neurons. To conclude, improvement by rhEPO of neuropsychiatric phenotypes may partly owe to restrictive control over interneurons, facilitating re-connectivity and synapse development.
- recombinant human erythropoietin / Max Planck Institute, Pfizer
Forebrain specific loss of erythropoietin provokes a compensatory upregulation of different EPO receptors (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_8503;
Using our single-nuclei-RNA-seq dataset, we identify forebrain expression of Emx mainly in excitatory neurons with no alterations upon EPO. Collectively, these data explain the lack of behavioral and cognitive consequences on forebrain-wide elimination of EPO.
- | VPM1002 / SAKK, Serum Institute of India
Enrollment change, Trial withdrawal: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa (clinicaltrials.gov) - Aug 5, 2024
P1/2, N=0, Withdrawn, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Collectively, these data explain the lack of behavioral and cognitive consequences on forebrain-wide elimination of EPO. N=480 --> 0 | Not yet recruiting --> Withdrawn
- |||| VPM1002 / SAKK, Serum Institute of India
Trial primary completion date: Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (clinicaltrials.gov) - May 28, 2024
P3, N=6940, Active, not recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
N=480 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Aug 2023 --> Dec 2025
- ||| VPM1002 / SAKK, Serum Institute of India
Trial completion date: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (clinicaltrials.gov) - Apr 8, 2024
P2/3, N=2000, Active, not recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
Trial primary completion date: Aug 2023 --> Dec 2025 Trial completion date: Feb 2024 --> Jul 2024
- | VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial primary completion date: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa (clinicaltrials.gov) - Mar 26, 2024
P1/2, N=480, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Trial completion date: Feb 2024 --> Jul 2024 Trial completion date: Oct 2026 --> Jul 2027 | Trial primary completion date: Oct 2026 --> Jul 2027
- || recombinant human erythropoietin / Max Planck Institute, Pfizer
Clinical, Journal: Effects of erythropoietin on cognitive impairment and prefrontal cortex activity across affective disorders: A randomized, double-blinded, placebo-controlled trial. (Pubmed Central) - Mar 23, 2024
P2
Nevertheless, the findings support the validity of dPFC target engagement as a biomarker model for pro-cognitive effects, according to which treatments that do not improve cognition should not modulate dPFC activity. EudraCT no.: 2016-004023-24; ClinicalTrials.gov identifier: NCT03315897.
- ||| recombinant human erythropoietin / Max Planck Institute, Pfizer
Clinical, Journal, Adverse events: Effect of erythropoietin on cognitive side-effects of electroconvulsive therapy in depression: A randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Feb 6, 2024
P2
The absence of global cognition changes with ECT and EPO, coupled with the specific impact of EPO on autobiographical memory recall speed and memory-related parietal cortex activity, suggests that assessing autobiographical memory may provide increased sensitivity in evaluating and potentially preventing cognitive side-effects of ECT. TRIAL REGISTRATIONS: ClinicalTrials.gov: NCT03339596, EudraCT no.: 2016-002326-36.
- | VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial primary completion date: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Dec 31, 2023
P2, N=5, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- || recombinant human erythropoietin / Max Planck Institute, Pfizer
Review, Journal: Neuroprotective Effects of Moderate Hypoxia: A Systematic Review. (Pubmed Central) - Dec 23, 2023
We identified 58 eligible studies (k = 8 human studies with N = 274 individuals; k = 48 animal studies) reporting the effects of hypoxia on cognition, motor function, neuroimaging, neuronal/synaptic morphology, inflammation, oxidative stress, erythropoietin, neurotrophins, and Alzheimer's disease markers...Low-dose intermittent or continuous hypoxia repeated for 30-240 min sessions, preferably in combination with motor-cognitive training, produced beneficial effects, and high-dose hypoxia with longer (?6 h) durations and chronic exposure produced more adverse effects. Larger and methodologically stronger translational studies are warranted.
- VPM1002 / SAKK, Serum Institute of India, Tecentriq (atezolizumab) / Roche
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19). (Level 1, West Hall; Poster Bd # M7) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_662;
P2
Chemotherapy with cisplatin (70mg/m2 day 1) and gemcitabine (1000mg/m2 day 1 & 8) q3w is started on day 22 and given for four cycles followed by radical cystectomy and lymphadenctomy...Accrual to the study is currently ongoing (NCT04630730). Clinical trial information: NCT04630730.
- | VPM1002 / SAKK, Serum Institute of India
Enrollment open: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Aug 23, 2023
P2, N=5, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Clinical trial information: NCT04630730. Active, not recruiting --> Recruiting
- | VPM1002 / SAKK, Serum Institute of India
Enrollment closed, Enrollment change: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Aug 21, 2023
P2, N=5, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Recruiting Suspended --> Active, not recruiting | N=46 --> 5
- | VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial initiation date, Trial primary completion date: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=480, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Suspended --> Active, not recruiting | N=46 --> 5 Trial completion date: Mar 2026 --> Oct 2026 | Initiation date: Sep 2023 --> Mar 2024 | Trial primary completion date: Mar 2026 --> Oct 2026
- || VPM1002 / SAKK, Serum Institute of India, Tecentriq (atezolizumab) / Roche
P2 data, Journal: Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). (Pubmed Central) - Jun 11, 2023
P2
Atezolizumab 1200?mg every 3 weeks is started together with rBCG and given for four cycles...Results will be made available by publication. NCT04630730.
- | VPM1002 / SAKK, Serum Institute of India
Trial completion, Trial completion date: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Apr 13, 2023
P1/2, N=39, Completed, Sponsor: Swiss Group for Clinical Cancer Research
NCT04630730. Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Mar 2023
- ||||| VPM1002 / SAKK, Serum Institute of India
Enrollment closed, Trial completion date, Trial primary completion date: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence (clinicaltrials.gov) - Apr 12, 2023
P2/3, N=2000, Active, not recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Mar 2023 Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Feb 2024 | Trial primary completion date: Feb 2022 --> Feb 2024
- recombinant human erythropoietin / Max Planck Institute, Pfizer
Pro-cognitive effects of intravenous erythropoietin in patientswith schizophrenia () - Mar 10, 2023 - Abstract #SIRS2023SIR_260;
Nonetheless, EPO constitutes a promisingapproach to mitigate cognitive deficits in several patient groups allowing to improve functionaloutcome. Hence, further efforts to establish optimal administration protocols and to promote awidespread use should be supported.KeywordKeywordsCognitive Decline in SchizophreniaPharmacological Treatmentneurodevelopmental disorderspsychosis, cognition, negative symptoms, neurobiologyPoster Award YesPoster Award Eligibility - Young Investigator YesPoster Award Eligibility - SIRS Membership NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationMishal * Qubad * Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe University2Karlotta Jacobs Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityCatherine Barnes-Scheufler Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityMareike Aichholzer Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannah Wendy Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannelore Ehrenreich Clinical Neuroscience, Max PlanckInstitute of Experimental Medicine,G
- | VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial initiation date, Trial primary completion date: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa (clinicaltrials.gov) - Mar 9, 2023
P1/2, N=480, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Hence, further efforts to establish optimal administration protocols and to promote awidespread use should be supported.KeywordKeywordsCognitive Decline in SchizophreniaPharmacological Treatmentneurodevelopmental disorderspsychosis, cognition, negative symptoms, neurobiologyPoster Award YesPoster Award Eligibility - Young Investigator YesPoster Award Eligibility - SIRS Membership NoPlease list all co-authors for this poster submission.* Presenting AuthorFirst Name Last Name AffiliationMishal * Qubad * Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe University2Karlotta Jacobs Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityCatherine Barnes-Scheufler Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityMareike Aichholzer Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannah Wendy Department of Psychiatry,Psychosomatic Medicine andPsychotherapy, University HospitalFrankfurt, Goethe UniversityHannelore Ehrenreich Clinical Neuroscience, Max PlanckInstitute of Experimental Medicine,G Trial completion date: Sep 2025 --> Mar 2026 | Initiation date: Mar 2023 --> Sep 2023 | Trial primary completion date: Sep 2025 --> Mar 2026
- || IMM-201 / Immodulon, RUTI (Mycobacterium tuberculosis cell wall nanofragmanets suspension) / Teodoro Garcia, VPM1002 / SAKK, Serum Institute of India
Clinical, Review, Journal: Safety and efficacy of tuberculosis vaccine candidates in low- and middle-income countries: a systematic review of randomised controlled clinical trials. (Pubmed Central) - Feb 28, 2023
Further efficacy trials for M72/AS01 are warranted to include additional populations at risk where safety has been demonstrated. Further safety trials are needed for the remaining vaccine candidates to confirm safety in vulnerable populations.
- | VPM1002 / SAKK, Serum Institute of India
Trial completion date: SAKK 06/14: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer (clinicaltrials.gov) - Jan 10, 2023
P1/2, N=39, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Further safety trials are needed for the remaining vaccine candidates to confirm safety in vulnerable populations. Trial completion date: Dec 2022 --> Jun 2023
- ||||| VPM1002 / SAKK, Serum Institute of India
Enrollment closed, Trial primary completion date: Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (clinicaltrials.gov) - Dec 20, 2022
P3, N=6940, Active, not recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
Trial completion date: Dec 2022 --> Jun 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2022 --> Aug 2023
- | recombinant human erythropoietin / Max Planck Institute, Pfizer
Journal: For decades against the mainstream - From erythropoietin and hypoxia as novel treatment strategies to deep phenotyping in neuropsychiatric disorders. (Pubmed Central) - Nov 18, 2022
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2022 --> Aug 2023 No abstract available
- ||| VPM1002 / SAKK, Serum Institute of India
Clinical, P3 data, Journal: VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including COVID-19 in the Elderly: a phase III randomised, double-blind, placebo-controlled, multicenter clinical study. (Pubmed Central) - Nov 16, 2022
P3
Vaccination with VPM1002 is well tolerated and seems to have a prophylactic effect against severe respiratory diseases in the elderly. (ClinicalTrials.gov: NCT04435379).
- | VPM1002 / SAKK, Serum Institute of India
Trial suspension: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Nov 8, 2022
P2, N=46, Suspended, Sponsor: Swiss Group for Clinical Cancer Research
(ClinicalTrials.gov: NCT04435379). Active, not recruiting --> Suspended
- | VPM1002 / SAKK, Serum Institute of India
Enrollment closed: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Oct 31, 2022
P2, N=46, Active, not recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Suspended Recruiting --> Active, not recruiting
- || VPM1002 / SAKK, Serum Institute of India
P2 data, Journal, Head-to-Head: Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. (Pubmed Central) - Sep 29, 2022
P2
Both vaccines were immunogenic, although responses were higher with the BCG vaccine. VPM1002 is currently being studied for efficacy and safety in a multicentric phase 3 clinical trial in babies in sub-Saharan Africa.
- | VPM1002 / SAKK, Serum Institute of India
New P1/2 trial: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa (clinicaltrials.gov) - Sep 14, 2022
P1/2, N=480, Not yet recruiting, Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- ||| VPM1002 / SAKK, Serum Institute of India
Clinical: Even if VPM remains a strong candidate as rBCG vaccine for TB and NMIBC it fails to match the levels of polyfunctional CD4 T cells as compared to BCG.@BishaiLab @tbivala1 Safety and immunogenicity of VPM1002 versus BCG in South African newbo... https://t.co/JXVmE0PqeW (Twitter) - Jul 12, 2022
- || recombinant human erythropoietin / Max Planck Institute, Pfizer
Review, Journal: Introducing the brain erythropoietin circle to explain adaptive brain hardware upgrade and improved performance. (Pubmed Central) - May 31, 2022
Here we delineate the brain EPO circle as working model explaining adaptive 'brain hardware upgrade' and improved performance. In this fundamental regulatory circle, neuronal networks, challenged by motor-cognitive tasks, drift into transient 'functional hypoxia', thereby triggering neuronal EPO/EPOR expression.
- |||||| VPM1002 / SAKK, Serum Institute of India
Clinical: Current Issue: A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive BC Recurrence After Conventional BCG Therapy: SAKK 06/14 https://t.co/wlSV4oY4Yy @__Kyr__ @daniel_engeler @hefermehl @roghmann (Twitter) - May 24, 2022
- || VPM1002 / SAKK, Serum Institute of India
Clinical, P1/2 data, Journal: A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. (Pubmed Central) - May 15, 2022
P1/2
At 1 yr after treatment start, almost half of the patients remained recurrence-free after therapy with VPM100BC. The primary endpoint of the study was met and the therapy is safe and well tolerated.
- ||||| VPM1002 / SAKK, Serum Institute of India
Trial completion: COBRA: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity (clinicaltrials.gov) - Apr 15, 2022
P3, N=122, Completed, Sponsor: University Health Network, Toronto
The primary endpoint of the study was met and the therapy is safe and well tolerated. Active, not recruiting --> Completed
- | VPM1002 / SAKK, Serum Institute of India
Enrollment open: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Apr 13, 2022
P2, N=46, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || recombinant human erythropoietin / Max Planck Institute, Pfizer
Clinical, Journal: Brain erythropoietin fine-tunes a counterbalance between neurodifferentiation and microglia in the adult hippocampus. (Pubmed Central) - Feb 12, 2022
Surprisingly, EPO affects microglia in phases, initially by inducing apoptosis, later by reducing proliferation, and overall dampens microglia activity and metabolism, as verified by selective genetic targeting of either the microglial or pyramidal neuronal EPO receptor. We suggest that during accelerating neuronal differentiation, EPO acts as regulator of the CSF1R-dependent microglia.
- | VPM1002 / SAKK, Serum Institute of India
Journal: An Update on Tuberculosis Vaccines. (Pubmed Central) - Jan 27, 2022
Each vaccine's immunogenicity, safety, and efficacy are tested in preclinical animal models and further validated through various phases of clinical trials. This chapter summarizes the various TB vaccine candidates under different clinical trial stages and promises better protection against TB.
- VPM1002 / SAKK, Serum Institute of India
3-year results of a phase I/II single arm clinical trial of recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC immunotherapy in non-muscle-invasive bladder cancer recurrence after conventional BCG therapy – SAKK 06/14 (Yellow Area, Room Forum) - Dec 22, 2021 - Abstract #EAU2022EAU_2183;
- || VPM1002 / SAKK, Serum Institute of India
Review, Journal: Vaccine Development Against Tuberculosis Over the Last 140 Years: Failure as Part of Success. (Pubmed Central) - Oct 27, 2021
It is hoped that highly efficacious vaccines against TB will become available even though it remains unclear whether and when this ambition can be accomplished. None the less it is clear that the goal of reducing TB morbidity and mortality by 90% or 95%, respectively, by 2030 as proposed by the World Health Organization depends significantly on better vaccines.
- ||||||| VPM1002 / SAKK, Serum Institute of India
Trial completion: Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic (clinicaltrials.gov) - Oct 26, 2021
P3, N=2038, Completed, Sponsor: Vakzine Projekt Management GmbH
None the less it is clear that the goal of reducing TB morbidity and mortality by 90% or 95%, respectively, by 2030 as proposed by the World Health Organization depends significantly on better vaccines. Active, not recruiting --> Completed
- | VPM1002 / SAKK, Serum Institute of India
Journal: Vaccination Strategies Against Mycobacterium tuberculosis: BCG and Beyond. (Pubmed Central) - Oct 22, 2021
Promising candidates include new generation of live recombinant BCG (rBCG) vaccines, VPM1002, which are deleted in one or two virulence genes...The former vaccine has passed phase IIb in clinical trials involving South African infants and adults. Thus, with an aim of elimination of TB by 2050, all these cumulative efforts to develop a better TB vaccine possibly is new hope for positive outcomes.
- || recombinant human erythropoietin / Trillium Therap, Max Planck Institute
Clinical, Review, Journal: Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues. (Pubmed Central) - Oct 10, 2021
Substitution of EPO may-among other beneficial EPO effects in severe COVID-19-circumvent downstream consequences of the 'hypoxia paradox'. A double-blind, placebo-controlled, randomized clinical trial for proof-of-concept is warranted.
- |||| VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial primary completion date: Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (clinicaltrials.gov) - Sep 29, 2021
P3, N=6940, Recruiting, Sponsor: Serum Institute of India Pvt. Ltd.
A double-blind, placebo-controlled, randomized clinical trial for proof-of-concept is warranted. Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jul 2023 --> Nov 2022
- | VPM1002 / SAKK, Serum Institute of India
Trial completion date, Trial initiation date, Trial primary completion date: SAKK 06/19: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (clinicaltrials.gov) - Sep 26, 2021
P2, N=46, Not yet recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jul 2023 --> Nov 2022 Trial completion date: Sep 2029 --> Jun 2030 | Initiation date: Jul 2021 --> Dec 2021 | Trial primary completion date: Sep 2025 --> Jun 2026
- | recombinant human erythropoietin / Trillium Therap, Max Planck Institute
Journal: CaMKIIα Expressing Neurons to Report Activity-Related Endogenous Hypoxia upon Motor-Cognitive Challenge. (Pubmed Central) - May 13, 2021
We previously introduced the brain erythropoietin (EPO) circle as a model to explain the adaptive 'brain hardware upgrade' and enhanced performance...To conclude, task-associated activity triggers neuronal functional hypoxia as a local and brain-wide reaction mediating adaptive neuroplasticity. Hypoxia-induced genes such as EPO drive neuronal differentiation, brain maturation, and improved performance.
- || VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
Review, Journal: Towards new TB vaccines. (Pubmed Central) - Apr 28, 2021
This encompasses the innate, adaptive, mucosal and humoral immune systems. Though MVA85A did not improve protection compared with BCG alone in a large-scale clinical trial, the correlates of protection this has revealed, in addition to promising results from candidate such as VPM1002, M72/ASO1E and H56:IC31 point to a brighter future in the field of TB vaccine development.
- VPM1002 / Max Planck Institute, SAKK, Serum Institute of India
[VIRTUAL] Results of a phase I/II single arm clinical trial assessing the recombinant Bacillus Calmette-Guérin (rBCG) VPM1002BC in patients with non muscle-invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14 (Virtual Room 7) - Apr 27, 2021 - Abstract #EAU2021EAU_1319;